UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 14, 2013
(Exact name of registrant as specified in its charter)
2030 DOW CENTER, MIDLAND, MICHIGAN 48674
Item 8.01 | Other Events |
The agreement (the “Agreement”) listed below is required to be filed as an exhibit to The Dow Chemical Company (the “Company”) Annual Report on Form 10-K for the year ended December 31, 2012 (the “10-K”). For administrative convenience and to avoid further increasing the size of the 10-K, the Company is filing the Agreement as an exhibit to this optional Current Report on Form 8-K and will incorporate the Agreement into the 10-K by reference hereto.
Item 9.01 | Financial Statements and Exhibits |
(d) | Exhibits. |
Exhibit No. | Description |
99.1 | First Amendment to the Shareholders’ Agreement, effective as of June 1, 2012, among Performance Chemicals Holding Company, Dow Saudi Arabia Holding B.V., Saudi Arabian Oil Company, Dow Europe Holding B.V. and the Company (portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission as part of an application for confidential treatment pursuant to the Securities Exchange Act of 1934, as amended). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE DOW CHEMICAL COMPANY
Registrant
Dated: February 14, 2013
/s/ Ronald C. Edmonds | ||
Ronald C. Edmonds | ||
Vice President and Controller |
EXHIBIT INDEX
Exhibit No. | Description |
99.1 | First Amendment to the Shareholders’ Agreement, effective as of June 1, 2012, among Performance Chemicals Holding Company, Dow Saudi Arabia Holding B.V., Saudi Arabian Oil Company, Dow Europe Holding B.V. and the Company (portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission as part of an application for confidential treatment pursuant to the Securities Exchange Act of 1934, as amended). |